NEWS
MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery
FOR IMMEDIATE RELEASE West Chester, PA, September 12, 2024, 6:01 am Eastern Standard Time (Business Wire) –Molecular Targeting Technologies,…
MTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing Summit
FOR IMMEDIATE RELEASE September 11, 2024, 6:01 am Eastern Standard Time, West Chester, PA (Business Wire) Molecular Targeting Technologies,…
MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE Radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
FOR IMMEDIATE RELEASE West Chester, PA, May 21, 2024, 6:01 am Eastern Standard Time (Business Wire)–Molecular Targeting Technologies, Inc.…
MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
FOR IMMEDIATE RELEASE West Chester, PA, and Singapore, September 12, 2023 — Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage…
Read more MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore receiveHSA approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
FOR IMMEDIATE RELEASE West Chester, PA, and Singapore, August 2, 2023 — Molecular Targeting Technologies, Inc. (MTTI), and its…
MTTI Highlights Promising One-Year Follow-Up on Ebtate Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion
FOR IMMEDIATE RELEASE West Chester, PA June 21, 2023 — Molecular Targeting Technologies, Inc. (MTTI) announced promising results from…
ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular
Ready to learn more?
Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals
